Esko WP
Vertex monopoly of the cystic fibrosis space signalled by another label expansion
On 28 April, the European Commission (EC) approved the label expansion for Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor + ivacaftor) for the treatment of cystic fibrosis (CF) in all patients aged 12 years and older who are heterozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation (F), regardless of the other mutation type, either gating (G) or residual function (RF) mutations.
Late-Stage Customization in Clinical Supplies by Introducing Just in Time Labeling
The Pros and Cons of Just in Time Labelling
Falsified Medicines Directive – Preparing for Global Compliance in Packaging and Labelling
Industry Viewpoints: Finding the Right Packaging Solution
The Use of Smart Packaging in the Health Care Space
